FDA strategies to prevent and respond to drug shortages: finding a better way to predict and prevent company closures.

To stave off a shortage of doxorubicin in 2011 and 2012, the FDA expedited the approval of a company's unapproved manufacturing process. Paying companies sufficiently so that they can invest in their facilities when needed is just one of many steps that could be taken to rectify future shortages.